Article

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

2023-09-17

Abstract excerpt

The COVID-19 pandemic has led to over 760 million cases and 6.9 million deaths worldwide. To mitigate the loss of lives, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of the virus...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc566fb9-8c7f-5562-b120-40cd9b0446e4
DOI: 10.1101/2023.09.14.557679

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibodyDOI 10.1101/2023.09.14.557679Read

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapySemantic proximity Read

Insights into the Dynamics of SARS-CoV-2 viral-Host interaction and Immune ResponseSemantic proximity Read

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodiesSemantic proximity Read

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.Semantic proximity Read

Persistent SARS-CoV-2 Infection in Patients With Secondary Antibody Deficiency: Successful Clearance Following Combination Casirivimab and Imdevimab (REGN-COV2) Monoclonal Antibody TherapySemantic proximity Read

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatmentSemantic proximity Read

Insights into B Cell and Antibody Kinetics Against SARS-CoV-2 Variants Using Mathematical ModellingSemantic proximity Read

Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.Semantic proximity Read

Overcoming Variants Resistance in Monoclonal Antibody for Antiviral TherapySemantic proximity Read

Characterising heterogeneity and sero-reversion in antibody responses to mild SARS⍰CoV-2 infection: a cohort study using time series analysis and mechanistic modellingSemantic proximity Read

SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccinesSemantic proximity Read